Total Payments
$816,315
2024 Payments
$86,908
Companies
61
Transactions
1,932
Medicare Patients
1,994
Medicare Billing
$186,571
Payment Breakdown by Category
Other$679,070 (83.2%)
Travel$58,846 (7.2%)
Consulting$45,576 (5.6%)
Food & Beverage$32,519 (4.0%)
Education$244.05 (0.0%)
Gifts$59.40 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $679,070 | 625 | 83.2% |
| Travel and Lodging | $58,846 | 271 | 7.2% |
| Consulting Fee | $45,576 | 16 | 5.6% |
| Food and Beverage | $32,519 | 1,004 | 4.0% |
| Education | $244.05 | 15 | 0.0% |
| Gift | $59.40 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $433,714 | 871 | $0 (2024) |
| Novo Nordisk Inc | $275,469 | 356 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $46,628 | 112 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $26,288 | 130 | $0 (2019) |
| Mannkind Corporation | $25,190 | 139 | $0 (2024) |
| Corcept Therapeutics | $2,549 | 16 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $543.78 | 27 | $0 (2024) |
| ABBVIE INC. | $542.88 | 29 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $526.92 | 26 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $525.10 | 30 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $86,908 | 188 | Lilly USA, LLC ($62,737) |
| 2023 | $74,818 | 161 | Lilly USA, LLC ($53,419) |
| 2022 | $113,793 | 209 | Lilly USA, LLC ($67,408) |
| 2021 | $92,180 | 194 | Lilly USA, LLC ($56,543) |
| 2020 | $78,925 | 202 | Lilly USA, LLC ($67,528) |
| 2019 | $116,833 | 344 | Lilly USA, LLC ($57,598) |
| 2018 | $154,032 | 356 | Novo Nordisk Inc ($75,162) |
| 2017 | $98,826 | 278 | Novo Nordisk Inc ($49,594) |
All Payment Transactions
1,932 individual payment records from CMS Open Payments — Page 1 of 78
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 12/13/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $350.00 | General |
| Category: Obesity | ||||||
| 12/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.90 | General |
| Category: DIABETES | ||||||
| 12/05/2024 | Xeris Pharmaceuticals, Inc. | GVOKE HYPOPEN (Drug) | Food and Beverage | In-kind items and services | $21.38 | General |
| Category: Diabetes | ||||||
| 12/04/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $19.79 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 11/27/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 11/26/2024 | Mannkind Corporation | AFREZZA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: DIABETES MEDICINE | ||||||
| 11/19/2024 | Verity Pharmaceuticals Inc. | Tlando (Drug) | Food and Beverage | Cash or cash equivalent | $20.32 | General |
| Category: Testosterone Replacement Therapy (TRT) | ||||||
| 11/18/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 11/15/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 11/15/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $350.00 | General |
| Category: Obesity | ||||||
| 11/12/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 11/01/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 10/30/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
| 10/29/2024 | Corcept Therapeutics | Korlym (Drug) | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: Endocrinology | ||||||
| 10/23/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $20.85 | General |
| Category: DIABETES | ||||||
| 10/08/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Travel and Lodging | Cash or cash equivalent | $50.00 | General |
| Category: Diabetes | ||||||
| 10/08/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $46.29 | General |
| Category: Diabetes | ||||||
| 10/08/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $31.31 | General |
| Category: Diabetes | ||||||
| 09/24/2024 | Neurocrine Biosciences, Inc. | — | Food and Beverage | In-kind items and services | $19.08 | General |
| 09/23/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Consulting Fee | Cash or cash equivalent | $3,150.00 | General |
| Category: Diabetes | ||||||
| 09/23/2024 | Lilly USA, LLC | MOUNJARO (Drug) | Consulting Fee | Cash or cash equivalent | $1,225.00 | General |
| Category: Diabetes | ||||||
| 09/20/2024 | Novo Nordisk Inc | Rybelsus (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $750.00 | General |
| Category: Diabetes | ||||||
| 09/20/2024 | AIMMUNE THERAPEUTICS, INC. | ZENPEP (Drug) | Food and Beverage | In-kind items and services | $20.85 | General |
| Category: ENDOCRINE PANCREATIC INSUFFICIENCY | ||||||
| 09/19/2024 | Lilly USA, LLC | ZEPBOUND (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $700.00 | General |
| Category: Obesity | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 536 | 865 | $113,205 | $52,678 |
| 2022 | 10 | 528 | 802 | $106,990 | $49,978 |
| 2021 | 9 | 475 | 681 | $94,415 | $46,927 |
| 2020 | 9 | 455 | 599 | $77,160 | $36,988 |
Total Patients
1,994
Total Services
2,947
Medicare Billing
$186,571
Procedure Codes
37
All Medicare Procedures & Services
37 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 203 | 375 | $73,125 | $35,930 | 49.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 27 | 36 | $8,820 | $5,364 | 60.8% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2023 | 39 | 40 | $10,000 | $3,507 | 35.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2023 | 27 | 33 | $6,105 | $2,835 | 46.4% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2023 | 39 | 78 | $7,020 | $2,229 | 31.8% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2023 | 11 | 12 | $3,000 | $1,435 | 47.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 59 | 89 | $3,560 | $915.72 | 25.7% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2023 | 72 | 113 | $1,130 | $362.73 | 32.1% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2023 | 59 | 89 | $445.00 | $99.44 | 22.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 189 | 331 | $64,545 | $31,007 | 48.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 60 | 79 | $14,550 | $7,545 | 51.9% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 17 | 19 | $4,595 | $2,868 | 62.4% |
| 76536 | Ultrasound scan of head and neck soft tissue | Office | 2022 | 27 | 28 | $7,000 | $2,381 | 34.0% |
| 95250 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with provider supplied equipment | Office | 2022 | 15 | 15 | $3,750 | $1,862 | 49.7% |
| 95251 | Continuous monitoring of blood sugar level in tissue fluid using sensor under skin with interpretation and report | Office | 2022 | 33 | 57 | $5,130 | $1,638 | 31.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 17 | 21 | $3,045 | $1,405 | 46.1% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 52 | 74 | $2,960 | $835.03 | 28.2% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2022 | 67 | 105 | $1,050 | $339.98 | 32.4% |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | Office | 2022 | 51 | 73 | $365.00 | $96.83 | 26.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 145 | 230 | $44,430 | $24,064 | 54.2% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 88 | 135 | $24,695 | $13,452 | 54.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 23 | 23 | $6,900 | $2,931 | 42.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 35 | 40 | $5,720 | $2,549 | 44.6% |
| 76536 | Ultrasound of head and neck | Office | 2021 | 23 | 24 | $6,000 | $1,813 | 30.2% |
| 95251 | Ambulatory continuous glucose (sugar) including interpretation and report for a minimum of 72 hours | Office | 2021 | 20 | 36 | $3,240 | $1,062 | 32.8% |
About Dr. Misha Denham, DO
Dr. Misha Denham, DO is a Endocrinology, Diabetes & Metabolism healthcare provider based in Coral Gables, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/08/2005. The National Provider Identifier (NPI) number assigned to this provider is 1689659096.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Misha Denham, DO has received a total of $816,315 in payments from pharmaceutical and medical device companies, with $86,908 received in 2024. These payments were reported across 1,932 transactions from 61 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($679,070).
As a Medicare-enrolled provider, Denham has provided services to 1,994 Medicare beneficiaries, totaling 2,947 services with total Medicare billing of $186,571. Data is available for 4 years (2020–2023), covering 37 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Coral Gables, FL
- Active Since 12/08/2005
- Last Updated 01/17/2017
- Taxonomy Code 207RE0101X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1689659096
Products in Payments
- TRULICITY (Drug) $225,276
- MOUNJARO (Drug) $111,205
- Ozempic (Drug) $72,787
- Victoza (Drug) $61,068
- ZEPBOUND (Drug) $51,792
- Rybelsus (Drug) $47,924
- Tresiba (Drug) $36,087
- STEGLATRO (Drug) $34,923
- INVOKANA (Drug) $26,323
- AFREZZA (Drug) $25,190
- RYBELSUS (Drug) $24,814
- BAQSIMI (Drug) $20,901
- JANUVIA (Drug) $8,614
- Xultophy 100/3.6 (Drug) $7,052
- Korlym (Drug) $2,549
- JARDIANCE (Drug) $634.87
- Vascepa (Drug) $399.19
- HUMULIN (Drug) $393.38
- Omnipod (Device) $384.23
- Saxenda (Drug) $309.50
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Coral Gables
Angela Gomez, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $1,902
Endocrinology, Diabetes & Metabolism $1,902
Dr. Wilfredo Bravo, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $196.17
Endocrinology, Diabetes & Metabolism $196.17
Dianelys Mendez, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $127.27
Endocrinology, Diabetes & Metabolism $127.27